---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AHFS | American Hospital Formulary Service |
| BLA | Biologics license application |
| CGM | Continuous glucose monitoring |
| CI | Confidence interval |
| CT | Computed tomography |
| ECOG | Eastern Cooperative Oncology Group |
| ENDO | Annual meeting of the Endocrine Society |
| ENETS | European Neuroendocrine Tumor Society |
| ESMO | European Society for Medical Oncology |
| EU | European Union |
| EUS | Endoscopic ultrasound |
| FDA | U.S. Food and Drug Administration |
| GEP-NET | Gastroenteropancreatic neuroendocrine tumor |
| GLP-1 | Glucagon-like peptide-1 |
| HI | Hyperinsulinism |
| HR | Hazard ratio |
| IGF-1 | Insulin-like growth factor 1 |
| IGF-2, IGF-II | Insulin-like growth factor 2 |
| IND | Investigational new drug application |
| INN | International nonproprietary name |
| IV | Intravenous |
| JNETS | Japan Neuroendocrine Tumor Society |
| KATP | ATP-sensitive potassium channel |
| LAR | Long-acting release |
| MEN 1 | Multiple endocrine neoplasia type 1 |
| mTOR | Mechanistic target of rapamycin |
| NANETS | North American Neuroendocrine Tumor Society |
| NICTH | Non-islet cell tumor hypoglycemia |
| PET | Positron emission tomography |
| PRRT | Peptide receptor radionuclide therapy |
| SEC | U.S. Securities and Exchange Commission |
| SEER | Surveillance, Epidemiology, and End Results Program |
| SMBG | Self-monitored blood glucose |
| SPECT | Single-photon emission computed tomography |
| UK | United Kingdom |
| WHO | World Health Organization |

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
